After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Billing software fixes are lifting collection rates, but the reimbursement framework behind them remains a variable investors must weigh.
Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Karan Patel - Piper Sandler & Co., Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Fulgent Genetics Q3 2026 Conference Call and Webcast Call. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.
Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company reaffirmed its full-year revenue forecast and narrowed its projected loss.
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results: Revenue of $90.4 million GAAP loss of $13.2 million, or $(0.48) per share Non-GAAP loss of $2.4 million, or $(0.09) per share Adjusted EBITDA loss of $7.5 million No.
Fulgent Genetics (NASDAQ: FLGT - Get Free Report) and Agilon Health (NYSE: AGL - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Valuation and Earnings This table compares Fulgent
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q.
Corient Private Wealth LP cut its stake in Fulgent Genetics, Inc. (NASDAQ: FLGT) by 34.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,394 shares of the company's stock after selling 24,261 shares during the period. Corient Private Wealth
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.